EU/3/12/1028: Orphan designation for the treatment of progressive familial intrahepatic cholestasis

(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid

Overview

(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid has been authorised in the EU as Bylvay since 16 July 2021.

On 17 July 2012, orphan designation (EU/3/12/1028) was granted by the European Commission to Albireo AB, Sweden, for (2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid for the treatment of progressive familial intrahepatic cholestasis.

Key facts

Active substance
(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid
Intended use
Treatment of progressive familial intrahepatic cholestasis
Orphan designation status
Positive
EU designation number
EU/3/12/1028
Date of designation
17/07/2012
Sponsor

Albireo AB
Arvid Wallgrens Backe 20
Goteborgs Annedal
413 46 Goteborg Vastra 
Gotalands Lan
Sweden
E-mail: info@albireopharma.com

Review of designation

The Committee for Orphan Medicinal Products reviewed the orphan designation of Bylvay at the time of marketing authorisation, and confirmed that the orphan designation should be maintained. 

More information is available in the PDF icon orphan medicine assessment report .

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating